TNK THERAPEUTICS
TNK Therapeutics develops chimeric antigen receptor immunotherapy programs.
TNK THERAPEUTICS
Industry:
Biotechnology Health Care
Founded:
2015-01-01
Address:
San Diego, California, United States
Country:
United States
Total Employee:
1+
Status:
Active
Similar Organizations
IMTherapeutics
IM Therapeutics develops personalized immuno-therapeutic drugs.
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-11-17 | Virttu Biologics | Virttu Biologics acquired by TNK Therapeutics | N/A |
More informations about "TNK Therapeutics"
TNK Therapeutics - Crunchbase Company Profile & Funding
TNK Therapeutics is located in San Diego, California, United States. Who are TNK Therapeutics 's competitors? Alternatives and possible competitors to TNK Therapeutics may include …See details»
TNK Therapeutics - 2025 Company Profile - Tracxn
TNK Therapeutics is an unfunded company based in San Diego (United States), founded in 2015. It operates as a Developing CAR.TNKs (Chimeric Antigen Receptor Tumor-attacking …See details»
SEC.gov | HOME
TNK Therapeutics is a subsidiary of Sorrento Therapeutics that is focused on the development and commercialization of cellular therapies to address unmet medical needs in oncology. TNK …See details»
TNK Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for TNK Therapeutics, Inc. of San Diego, CA. Get the latest business insights from Dun & Bradstreet.See details»
Sorrento Therapeutics Announces Closing of its …
Apr 28, 2017 TNK Therapeutics is a subsidiary of Sorrento Therapeutics that is focused on the development and commercialization of cellular therapies to …See details»
SORRENTO’S TNK THERAPEUTICS SUBSIDIARY ACQUIRES - SEC.gov
San Diego, CA – August 10, 2015 — Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) announced today that its wholly-owned subsidiary, TNK Therapeutics, Inc., has acquired …See details»
TNK Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials
Explore TNK Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 1 news, and 16 literature, Drug:Anti-PSMA chimeric antigen receptor T cell …See details»
Sorrento Establishes TNK Therapeutics Subsidiary with Focus on …
May 18, 2015 Forward-looking statements include statements about TNK Therapeutics' prospects, Sorrento's expectations for adoptive cellular immunotherapies and Sorrento's …See details»
TNK Therapeutics Inc Company Profile, Financial and ... - digitGaps
TNK Therapeutics, Inc. develops chimeric antigen receptor immunotherapy programs. The company was founded in 2015 and is based in San Diego, California. TNK Therapeutics, Inc. …See details»
TNK Therapeutics - Life-Sciences-Europe.com
Apr 4, 2020 Advertisement. Organisation › Details TNK Therapeutics. Sorrento Therapeutics, Inc. is a publicly-traded, development-stage biopharmaceutical company engaged in the …See details»
Sorrento Announces Closing Of Its Acquisition Of Virttu Biologics
Apr 28, 2017 As announced by Sorrento on November 16, 2016, TNK and Virttu entered into a binding term sheet setting forth the terms and conditions by which TNK would purchase all of …See details»
TNK Therapeutics, Inc. (TNK Therapeutics, Inc.) - 药物管线_专利_临 …
了解TNK Therapeutics, Inc. (TNK Therapeutics, Inc.)公司的药物管线，治疗领域，技术平台，以及它的2项临床试验, 4篇新闻和16篇文献，药物:HSV-1716，Anti-PSMA CAR-T cell therapy …See details»
Sorrento Unit Buys CAR-T Programs, Technology for ... - BioSpace
SAN DIEGO, Aug. 10, 2015 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento) announced today that its wholly-owned subsidiary, TNK Therapeutics, Inc., has …See details»
Sorrento's TNK Therapeutics Subsidiary to Acquire Virttu Biologics
Nov 24, 2016 TNK Therapeutics Inc ("TNK"), a subsidiary of Sorrento Therapeutics Inc has entered into a binding term sheet to acquire Virttu Biologics Limited ("Virttu"). Virttu, based in …See details»
Sorrento Forms Immunotherapy Subsidiary - DCAT Value Chain …
May 18, 2015 Sorrento Therapeutics, Inc. has formed a wholly owned subsidiary, TNK Therapeutics, Inc., which will focus on on developing CAR.TNKs (Chimeric Antigen Receptor …See details»
Anti-PSMA chimeric antigen receptor T cell therapy - TNK …
07 Aug 2015 TNK Therapeutics, a subsidiary of Sorrento Therapeutics, acquires BDL Products and CARgenix (Sorrento Therapeutics 8-K, August 2015) You need to be a logged in or …See details»
Pivotal Therapeutics Inc Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Pivotal Therapeutics Inc of Woodbridge, ON. Get the latest business insights from Dun & Bradstreet.See details»
Saol Therapeutics Announces Major Clinical Milestones Across …
2 days ago SL1009 targets a 2025 FDA decision for Pyruvate Dehydrogenase Complex Deficiency (PDCD), while SL1002 advances toward Phase III trials for osteoarthritis knee pain …See details»
Woodbridge biotech gets FDA ‘orphan’ status for anti-tumor drug
Federal regulators have deemed a Woodbridge biotechnology company’s tumor-fighting therapy an ‘orphan’ drug, making it eligible for financial incentives. AlloMek Therapeutics earned the …See details»
Safety and Effectiveness for Tenecteplase and Alteplase in Acute ...
Mar 12, 2025 Furthermore, including findings from another meta-analysis, there were no significant differences in rates of sICH or mortality between the 2 thrombolytics. 8,19 The …See details»